HOLLISTON, Mass., April 26, 2017 /PRNewswire/ -- Biostage
Inc., (Nasdaq: BSTG), ("Biostage" or the "Company), a biotechnology
company developing bioengineered organ implants to treat cancers
and other life-threatening conditions of the esophagus, bronchus
and trachea, announced today that it will participate in the
Alliance for Regenerative Medicine's ("ARM") 5th Annual
Cell & Gene Therapy Investor Day being held on Thursday, April 27, 2017 in Boston, MA.
Jim McGorry, CEO of Biostage, will be available to participate
in one-on-one meetings with qualified members of the investment
community who are registered to attend the conference.
About ARM's Cell & Gene Therapy Investor Day
This
one-day, high impact program provides institutional, strategic and
venture investors with unique insight into the financing hypothesis
for advanced therapies-based treatment and tools. The event
includes clinical and commercial experts who are on-hand to address
specific questions regarding the outlook for these products, as
well as offer insight into how cell and gene therapies could impact
the standard of care in key therapeutic areas such as
cardiovascular disease, wound healing and tissue repair,
ophthalmology, neurodegenerative diseases, diabetes and oncology.
The program will include talks by key opinion leaders in the
industry, life science investment experts and analysts covering the
sector as well as presentations by more than 30 leading companies
from across the globe. For more information, please visit
www.arminvestorday.com.
About Biostage
Biostage is a biotechnology company
developing bioengineered organ implants based on the Company's new
Cellframe™ technology which combines a proprietary
biocompatible scaffold with a patient's own stem cells to create
Cellspan™ organ implants. Cellspan implants are being
developed to treat life-threatening conditions of the esophagus,
bronchus or trachea with the hope of dramatically improving the
treatment paradigm for patients. Based on its preclinical data,
Biostage has selected life-threatening conditions of the esophagus
as the initial clinical application of its technology.
Cellspan implants are currently being advanced and tested in
collaborative preclinical studies. Preclinical, large-animal safety
studies, conducted in compliance with the FDA Good Laboratory
Practice ("GLP") regulations, for the Company's Cellspan Esophageal
Implant product candidate are ongoing, in support of Biostage's
goal of filing an Investigational New Drug application ("IND") with
the U.S. FDA in the third quarter of 2017. The IND will seek
approval to initiate clinical trials for its esophageal implant
product candidate in humans.
For more information, please visit www.biostage.com and connect
with the Company on Twitter and LinkedIn.
Forward-Looking Statements:
Some of the statements in
this press release are "forward-looking" and are made pursuant to
the safe harbor provision of the Private Securities Litigation
Reform Act of 1995. These "forward-looking" statements in this
press release include, but are not limited to, statements relating
to the development expectations and regulatory approval of any of
our products, including those utilizing our Cellframe technology,
by the U.S. Food and Drug Administration, the European Medicines
Agency or otherwise, which expectations or approvals may not be
achieved or obtained on a timely basis or at all; or success with
respect to any collaborations, clinical trials and other
development and commercialization efforts of our products,
including those utilizing our Cellframe technology, which such
success may not be achieved or obtained on a timely basis or at
all. These statements involve risks and uncertainties that may
cause results to differ materially from the statements set forth in
this press release, including, among other things, our ability to
obtain and maintain regulatory approval for our products; plus
other factors described under the heading "Item 1A. Risk Factors"
in our Annual Report on Form 10-K for the fiscal year ended
December 31, 2016 or described in our
other public filings. Our results may also be affected by factors
of which we are not currently aware. The forward-looking statements
in this press release speak only as of the date of this press
release. Biostage expressly disclaims any obligation or undertaking
to release publicly any updates or revisions to such statements to
reflect any change in its expectations with regard thereto or any
changes in the events, conditions or circumstances on which any
such statement is based.
Investor Relations
Contacts:
|
|
Tom
McNaughton
|
Jenene
Thomas
|
Chief Financial
Officer
|
Jenene Thomas
Communications LLC
|
774-233-7321
|
(908)
938-1475
|
tmcnaughton@biostage.com
|
jtc@jenenethomascommunications.com
|
|
|
Media
Contacts:
|
|
David Schull or
Maggie Beller
|
|
Russo Partners
LLC
|
|
212-845-4271 or
646-942-5631
|
|
Email:
Maggie.beller@russopartnersllc.com
|
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/biostage-to-participate-at-the-alliance-for-regenerative-medicines-5th-annual-cell--gene-therapy-investor-day-300445610.html
SOURCE Biostage, Inc.